Sleep Treatment Education Program for Cancer Survivors: STEP-Together
1 other identifier
interventional
100
1 country
1
Brief Summary
This single-arm research study of off-treatment cancer survivors with self-reported symptoms of insomnia will test the Sleep Treatment Education Program Together (STEP-Together) intervention which is delivered as a synchronous group session by videoconference.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Jun 2025
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 12, 2024
CompletedFirst Posted
Study publicly available on registry
December 16, 2024
CompletedStudy Start
First participant enrolled
June 25, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 31, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2026
July 2, 2025
July 1, 2025
1.4 years
December 12, 2024
July 1, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change in Insomnia Severity Index (ISI) Score from Baseline to 8 weeks Post-Intervention
Assessed by the Insomnia Severity Index, a 7-item measure measuring insomnia over the previous two weeks with answers graded on a 5-point Likert scale, ranging from 0 "No Problem" to "4 "Very Severe" for a total score range of 0 to 28. A higher score reflects moderate to severe insomnia symptoms.
Baseline to 8 weeks post-intervention
Secondary Outcomes (3)
Change in Total Mood Disturbance (TMD) Scale from the Profile of Mood States - Short Form (POMS-SF) Score from Baseline to 8 weeks Post-Intervention
Baseline to 8 weeks post-intervention
Change in Perceived Cognitive impairment Scale from Baseline to 8 weeks Post-Intervention
Baseline to 8 weeks post-intervention
Change in Impact of Cognitive Function on Quality of Life Scale from Baseline to 8 weeks Post-Intervention
Baseline to 8 weeks post-intervention
Study Arms (1)
STEP-Together Intervention
EXPERIMENTALEnrolled participants will complete the educational intervention session (STEP-Together) delivered by an interventionist during an online group videoconference session. -Up to 12 participants will also take part in a coaching session 1 week after the virtual intervention session.
Interventions
STEP-Together is delivered in a single videoconference group session delivered live by a presenter. During the session, the participants are able to see and hear the presenter, view the presentation slides, and ask questions. The presentation includes educational information on the problem of insomnia after cancer and specific suggestions for improving sleep. Suggestions are presented in four sections addressing lifestyle issues, sleep environment, sleep timing, and managing expectations and challenges. During the course of the session, participants are asked to use these suggestions to develop an individual sleep action plan they will use to improve their sleep.
Coaching sessions are brief (\<1hour) sessions intended to support participants in implementing their personal sleep self-management plan. In the session, participants are asked to review their progress with their plan, report on areas of sucess and difficulty with adoption, and to problem solve with the study team as needed to support their sucessful implementation their plan.
Eligibility Criteria
You may qualify if:
- Age 18-89
- History of a cancer diagnosis (except non-melanoma skin cancer) ≥ 6 months prior
- No active cancer therapy (excluding chemoprevention) in the past four months, and no further therapy planned.
- Significant insomnia as evidenced by an Insomnia Severity Index score ≥ 8
- Regular access to the internet
- Able to read and write in English
You may not qualify if:
- Usual bedtime does not fall between 5:00 pm and 5:00 am.
- Employment in a position where falling asleep at work could impact public safety (such as air traffic-controller, operating heavy machinery).
- Ever diagnosed with Bipolar Disorder or with Seizure Disorder, currently taking medications to prevent a seizure, or have experienced a seizure in the prior 12 months.
- Any impairment (e.g., hearing, visual, cognitive) that interferes with the ability to complete all study procedures independently.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Christopher Recklitis, PhD, MPH
Dana-Farber Cancer Institute
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
December 12, 2024
First Posted
December 16, 2024
Study Start
June 25, 2025
Primary Completion (Estimated)
October 31, 2026
Study Completion (Estimated)
December 31, 2026
Last Updated
July 2, 2025
Record last verified: 2025-07
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP
- Time Frame
- Data can be shared no earlier than 1 year following the date of publication
- Access Criteria
- Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu
The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: \[contact information for Sponsor Investigator or designee\]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.